Is Viking Therapeutics Stock Going to $100?
Yahoo Finance ·
Shares of Viking Therapeutics ( VKTX 3.95% ) have climbed by 27% over the past month. The drugmaker is a serious candidate to make waves in the large and growing anti-obesity drug market. With several ongoing clinical trials, there could be important catalysts on the horizon. Viking's shares are currently trading at about $40 apiece. Could the stock soar over the next 18 months and reach $100? Viking Therapeutics' leading weight-loss candidate, VK2735, mimics the actions of two gut hormones, GLP-1 and GIP. The former helps control satiety, while the latter helps regulate blood glucose. Medicines that activate both pathways could deliver better weight loss than those that only mimic the GLP-1 hormone, as we have seen with Zepbound, a dual GLP-1 and GIP agonist that is currently the best-selling weight management drug. Viking Therapeutics' VK2735 is undergoing a pair of phase 3 studies in overweight or obese patients. One of them has also enrolled those with diabetes. We could see results from these studies within 12 to 18 months. That's likely the biggest catalyst on the horizon for Viking Therapeutics. However, the company is working on other candidates, including an oral formulation of VK2735, which should also start phase 3 studies by year-end (the one currently in late-stage trials is administered via subcutaneous injection). What if Viking Therapeutics posts strong clinical trial results for subcutaneous VK2735, perhaps showing that it could rival -- or even exceed -- Zepbound's efficacy? In that case, Viking Therapeutics' share price will soar. In the meantime, the company may also benefit if other drugmakers report disappointing clinical trial data for their weight-loss candidates. And elsewhere, Viking Therapeutics is running a study to test whether various doses and formulations of VK2735, given daily or weekly, can help patients keep the weight off.
DYAX Investor Sentiment
Bullish (Long) 51% · Bearish (Short) 49%
270 participants
Related News
- BlackRock High Yield ETF declares monthly distribution of $0.257212
- YieldMax TSLA Option Income Strategy ETF announces weekly distribution of $0.2813
- iShares Emerging Markets Bond Active ETF declares monthly distribution of $0.261885
- YieldMax TSM Option Income Strategy ETF announces weekly distribution of $0.1556
- YieldMax Short MSTR Option Income Strategy ETF announces weekly distribution of $0.6252
- YieldMax XOM Option Income Strategy ETF announces weekly distribution of $0.0697